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Epstein-Barr virus-encoded RNAs 
(EBERs) complement the loss of 
Herpesvirus telomerase RNA (vTR) 
in virus-induced tumor formation
Ahmed Kheimar  1,2 & Benedikt B. Kaufer  1
Marek’s disease virus (MDV) is an alphaherpesvirus that causes fatal lymphomas in chickens and is used 
as a natural virus-host model for herpesvirus-induced tumorigenesis. MDV encodes a telomerase RNA 
subunit (vTR) that is crucial for efficient MDV-induced lymphoma formation; however, the mechanism 
is not completely understood. Similarly, Epstein Barr-virus (EBV) encodes two RNAs (EBER-1 and EBER-
2) that are highly expressed in EBV-induced tumor cells, however their role in tumorigenesis remains 
unclear. Intriguingly, vTR and EBER-1 have interaction partners in common that are highly conserved 
in humans and chickens. Therefore, we investigated if EBER-1 and/or EBER-2 can complement the 
loss of vTR in MDV-induced tumor formation. We first deleted vTR (v∆vTR) and replaced it by either 
EBER-1 or EBER-2 in the very virulent RB-1B strain. Insertion of either EBER-1 or EBER-2 did not affect 
MDV replication and their expression levels were comparable to vTR in wild type virus. Intriguingly, 
EBER-2 restored tumor formation of MDV that lacks vTR. EBER-1 partially restored MDV oncogenicity, 
while tumor formation was severely impaired in chickens infected with v∆vTR. Our data provides the 
first evidence that EBERs possess tumor-promoting properties in vivo using this natural model for 
herpesvirus-tumorigenesis.
Marek’s disease virus (MDV) is a highly oncogenic alphaherpesvirus that infects chickens and causes the most 
frequent clinically-diagnosed cancer in the animal kingdom1,2. Upon infection, MDV efficiently replicates in B 
cells and subsequently predominantly transforms CD4 T cells, resulting in deadly lymphomas3,4. Solid lympho-
mas can be detected in various visceral organs as early as 3 weeks post infection and in up to 100% of infected 
susceptible animals1. Several viral factors have been discovered that contribute to cancer formation including the 
major oncoprotein Meq (Marek’s EcoRI-Q-encoded protein)5, the viral interleukin-8 (vIL-8)6,7, MDV-encoded 
miRNAs8,9 and the virus encoded telomerase RNA (vTR)10.
vTR is dispensable for viral replication in vitro and in vivo, but is crucial for MDV-induced malignant trans-
formation and is the most abundant viral transcripts in MDV-induced tumor cells11. It interacts with the chicken 
telomerase reverse transcriptase subunit (TERT) and enhances telomerase activity10,12. Intriguingly, MDV 
encoding a mutant vTR that does not mediate telomerase activity efficiently induced cancers as wild type virus13, 
demonstrating that the tumor-promoting functions of vTR are independent on its role of the telomerase com-
plex13. vTR not only interacts with TERT but also with the ribosomal protein L22 (RpL22), a ribosomal protein 
that plays an important role in T-cell development14,15 and transformation. Although vTR has been shown to 
re-localize RpL2213, it remains unclear if this process contributes to cellular transformation.
Another viral RNA that binds and re-localizes RpL22 is the Epstein-Barr virus (EBV)-encoded RNA 1 (EBER-
1). EBER-1 and the structurally related EBER-2 are highly expressed in EBV-latently infected16 and transformed 
cells17, however their role in transformation are still controversial. Deletion of both EBERs did not affect transfor-
mation of B cell in vitro18,19, while others observed a role of EBER-2 in EBV-induced B cell proliferation20. In an 
EBV mouse model, deletion of the EBERs from the EBV genome did not change the viral persistence in vivo com-
pared to wild type virus21; however, the tumor-promoting properties for EBERs were not assessed. Aside from 
RpL22, several factors have been shown to interact with EBER-1, including the Lupus erythematosis-associated 
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antigen (La)22 and the double-stranded-RNA-activated protein kinase (PKR)23,24. EBER-2 also interacts with La22 
as well as the transcription factor paired box protein 5 (PAX-5)25. Intriguingly, these factors are all conserved 
between humans and chickens.
In the current study, we investigated if EBER-1 and/or EBER-2 can complement the loss of vTR in 
MDV-induced tumor formation. We generated recombinant MDV-viruses that lack vTR and encode either 
EBER-1 or EBER-2 instead. Analysis of their replication properties in vitro and in vivo revealed that nei-
ther deletion of the entire vTR nor insertion of EBERs affects MDV replication. Deletion of the vTR severely 
impaired tumor formation. Intriguingly, expression of EBER-2 efficiently restored tumor formation, while 
EBER-1 only partially complemented the loss of vTR. Our study provides the first evidence that EBERs possess 
tumor-promoting effects in vivo using this natural animal model for herpesvirus-induced tumor formation.
Results
Generation and characterization of the recombinant viruses in vitro. To determine if EBERs can 
complement the loss of vTR, we generated recombinant viruses that encode either EBER-1 (vEBER-1) or EBER-2 
(vEBER-2) instead of vTR (Fig. 1A). EBER-1 and EBER-2 were sequentially introduced into the RB-1B MDV 
strain lacking the entire vTR (vΔvTR) (Fig. 1A) using en passant mutagenesis. In addition, a revertant virus 
(vRev) was generated in which vTR was restored in the original locus. Mutants were analyzed by RFLP, Sanger 
and Illumina MiSeq sequencing (coverage > 1000-fold) to confirm that the entire virus genome is correct. To 
determine if deletion of vTR or insertion of EBERs affects viral replication, we assessed the replication of the 
recombinant viruses. Plaque size assays revealed that the recombinant viruses replicated comparable to wild type 
Figure 1. Generation and characterization of the recombinant MDV mutants. (A) Overview of MDV genome 
with a focus on the vTR with its eight conserved regions (CR1-CR8). Recombinant viruses that either lack 
the entire vTR (v∆vTR), harbor EBER-1 (vEBER-1) or EBER-2 (vEBER-2) instead of vTR are shown below. 
The vTR sequences were completely restored in the revertant virus (vRev). (B) Plaque size assays of indicated 
recombinant viruses. The plaque sizes are shown as box plots with minimums and maximums. Results are 
shown as the means of three independent experiments (p > 0.05; one-way ANOVA, n = 150). (C) Multi-
step growth kinetics of indicated viruses. The average titer and standard deviations (error bar) are shown of 
triplicates of one independent experiment (p > 0.05; Kruskal-Wallis test).
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and revertant virus (Fig. 1B). We confirmed this observation using multi-step growth kinetics (Fig. 1C), high-
lighting that neither deletion of vTR nor insertion of EBERs alters MDV replication.
Recombinant viruses efficiently express EBERs. To determine if the EBERs are efficiently expressed 
during MDV replication, we infected CECs with the wild type or recombinant viruses and performed qRT-PCR. 
As expected, vTR was only expressed in wild type and revertant virus, while no vTR expression was detected 
upon deletion of the vTR gene (Fig. 2A). EBER-1 and EBER-2 were highly expressed in the corresponding recom-
binant viruses at copy numbers comparable to vTR in the wild type virus and revertant virus (Fig. 2B and C). No 
significant difference was observed for the expression of the viral ICP4 or the cellular GAPDH genes (Fig. 2D and 
E). Taken together, vEBER-1 and vEBER-2 efficiently expressed the expected EBER gene, while no vTR expression 
was detectable in both viruses.
EBERs complement the loss of vTR in MDV-induced tumor formation. To determine if EBERs can 
complement the loss of vTR in MDV-induced tumor formation, we infected one-day old chickens subcutane-
ously with 2,000 PFU of vRB-1B, v∆vTR, vEBER-1, vEBER-2 or vRev and monitored the onset of clinical symp-
toms and tumor formation. To investigate if the recombinant viruses replicated efficiently in infected animals, 
we quantified viral genome copies in the blood by qPCR. Replication of vΔvTR, vEBER-1 and EBER-2 was not 
significantly altered compared to the wild type and the revertant virus (Fig. 3A), indicating that expression of the 
EBERs did not affect MDV replication in vivo.
During the course of infection, animals were monitored for the development of clinical symptoms and tumors. 
In the absence of vTR, tumor incidence was significantly reduced (p < 0.0125) (Fig. 3B) as described previously11. 
Figure 2. Quantification of vTR and EBERs expression in infected cells. One million CECs were infected with 
1000 PFU of indicated viruses, RNA isolated 6 dpi and qRT-PCR performed. The mean copy numbers of (A) 
vTR, (B) EBER-1 and (C) EBER-2 is shown for indicated viruses relative to the expression levels of the cellular 
GAPDH and the viral ICP4 (p > 0.05; Kruskal-Wallis). Expression of (D) the viral ICP4 and (E) the cellular 
GAPDH control genes was not statistically different between the indicated viruses (p > 0.05; Kruskal-Wallis). 
Results are shown as means of three independent experiments with standard errors.
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Intriguingly, the tumor incidence of vEBER-2 was comparable to the wild type and revertant virus indicating that 
the expression of EBER-2 completely restored tumor formation. Expression of EBER-1 only partially restored 
MDV-induced tumor formation, as vEBER-1 (40%) only showed a mild increase in tumor incidence compared 
to vΔvTR (28%; Fig. 3B). To confirm that the EBERs are efficiently expressed in MDV-induced tumor cells, we 
quantified EBER-1 and EBER-2 expression in tumor tissue by qRT-PCR. Both EBER-1 and EBER-2 were highly 
expressed and at comparable levels (Supplementary Fig. 1).
Figure 3. EBERs complement for the loss of vTR in MDV-induced tumor formation. (A) qPCR detecting 
MDV genome copies in the blood of chickens infected with vRB-1B (n = 9), v∆vTR (n = 25), vEBER-1 (n = 25), 
vEBER-2 (n = 23) or vRev (n = 24). Means MDV genome copies per million cells are shown for the indicated 
time points. (p > 0.05; Kruskal-Wallis test). (B) Tumor incidence in chickens infected with indicated viruses. 
Tumor incidence is shown in a percent of animals per group. Significant differences are indicated by an asterisk 
(p < 0.0125; Fisher’s exact test). (C) Mean number of gross tumors per animals infected with the indicated 
viruses, Significant differences are indicated by an asterisk (p < 0.0125; Fisher’s exact test).
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To elucidate the effect of EBERs expression in tumor dissemination, we determined the numbers of organs 
with gross tumors during necropsy. The average number of the tumors per animals was significantly reduced 
in the absence of vTR compared to wild type and revertant virus (Fig. 3C). Most importantly, EBER-2 expres-
sion also efficiently restored tumor dissemination. No significant difference in the average number of tumors 
was observed between the animals infected with vEBER-2 compared to the wild type or revertant virus. A par-
tial restoration was observed for vEBER-1 when compared to v∆vTR. Taken together, our data demonstrates 
that the EBV-encoded- EBERs can either fully (EBER-2) or partially (EBER-1) complement the loss of vTR in 
MDV-induced tumor formation using this small animal model for herpesvirus-induced oncogenesis. Our study 
provides thereby the first evidence that EBERs possess tumor promoting function in vivo.
Discussion
vTR plays an important role in MDV-induced tumor formation, however the mechanism remains poorly under-
stood. We recently demonstrated that vTR possesses tumor-promoting functions that are independent of its role 
in the telomerase activity13. The telomerase activity mediated by vTR only contributed to the rapid onset of tum-
ors; however, tumor incidence and dissemination was not affected when incorporation of vTR into the telomerase 
complex was abrogated13. Therefore, vTR likely drives virus-induced transformation via the interaction with the 
ribosomal protein RpL22 and/or other cellular factors. Intriguingly, both vTR and EBER-1 interact and re-localize 
RpL2213, which is almost completely conserved between humans and chickens. Therefore, we set to determine if 
EBER-1 and/or EBER-2 can complement the loss of vTR in MDV-induced tumor formation.
We generated recombinant MDVs that express either EBER-1 or EBER-2 instead of vTR. Virus replication was 
not affected in vitro and in vivo, revealing that neither deletion of the entire vTR nor insertion of the EBERs affects 
MDV replication. Our data on the complete deletion of vTR is therefore consistent with the previously published 
partial deletions of the conserved regions (CR1-CR4) of vTR11. To confirm the efficient expression of EBER-1 and 
EBER-2, we performed qRT-PCR and we could demonstrate that EBERs were highly overexpressed. The observed 
expression levels of EBERs in MDV infected cells were also comparable to latently infected cells and EBV-induced 
cancers (>106 per cell)16,26. EBER expression levels were also similar to vTR in wild type virus and revertant virus 
due to the strong nature of the vTR promoter12. Expression levels of vTR, and likely also the EBERs, play a crucial 
role in the transformation process as viruses that expressed vTR at lower levels were severely impaired in tumor 
formation in vivo27.
To determine the effect of the complete deletion of vTR and if the EBERs can complement the loss of vTR, 
we infected SPF chickens with the recombinant viruses. As expected, deletion of the entire vTR severely atten-
uated MDV and is consistent with the partial deletion of the gene published previously11. Intriguingly, EBER-1 
that also interacts and re-localizes RpL22 only partially restored MDV-induced tumor formation, suggesting 
that this interaction could indeed play a minor role in the cellular transformation. However, certainly also other 
interaction partners or mechanisms are responsible for vTR mediated tumor formation. Alternatively, the dysreg-
ulation of RpL22 could differ between EBER-1 and vTR, possibly due to differences in the binding affinity to the 
ribosomal protein as observed previously11. Surprisingly, EBER-2 expression efficiently restored MDV-induced 
tumor formation and metastasis of a virus that lacks vTR. Intriguingly, EBER-2 has been previously shown to 
inhibit apoptosis28,29 and increase cell-proliferation30, which could contribute to the increased tumor incidence 
of the EBER-2 expressing virus. It remains unknown which interaction partners of EBER-2 mediate these effects 
and if they are conserved between humans and chickens as La and PAX-5. We will address these aspects and if 
conserved stem loop structures in EBER-1, EBER-2 and vTR (Supplementary Fig. 2) mediate these functions in 
future studies.
Taken together, our data demonstrate that EBER-1 and EBER-2 possess tumor promoting activity that can 
complement the activity of vTR in MDV-induced transformation. Future studies will focus on the conserved 
interaction partners and possible mechanism(s) for EBER mediated transformation using this natural virus-host 
animal model for herpesvirus induced tumor formation.
Methods
Cells and viruses. Chicken embryo cells (CECs) were prepared from 11-day old Valo specific-pathogen free 
(SPF) embryos (ValoBioMedia) as described previously31. CECs were propagated in MEM supplemented with 
10% FCS, 1% penicillin/streptomycin at 37 °C under a 5% CO2 atmosphere.
Generation of recombinant viruses. Recombinant viruses encoding EBER-1 or EBER-2 instead of vTR 
were generated using a bacterial artificial chromosome (BAC) of the very virulent MDV strain RB-1B that lacks 
most of the internal repeat long region (IRL; pRB-1B∆IRL)7, which is rapidly restored upon virus reconstitu-
tion. Therefore, only one copy of vTR region had to be manipulated by two-step Red-mediated mutagenesis as 
described previously32,33, while the resulting recombinant virus contained the substitution/deletion in both loci7. 
First, we deleted the entire vTR, then sequentially introduced either EBER-1 (vEBER-1) or EBER-2 (vEBER-2) of 
the B95-8 EBV-strain (RefSeq M80517.1), allowing EBER expression under control of the native vTR promoter. 
In addition, a revertant virus (vRev) was generated in which the original vTR locus restored. Primers used for 
mutagenesis are listed in Table 1. Recombinant BAC clones were confirmed by RFLP, PCR and Sanger sequencing 
of the target area (Supplementary Fig. 3). In addition, we performed Illumina MiSeq sequencing to ensure that 
the entire nucleotide sequence of the constructs is correct. Recombinant viruses were reconstituted by transfec-
tion of CECs with BAC DNA as described previously7,34.
Quantification of vTR and EBERs expression. vTR and EBER expression levels were determined in 
vitro and in vivo by qRT-PCR. Briefly, total RNA was extracted from viral infected CECs using the RNeasy Plus 
Mini Kit (Qiagen) and from tumor tissue using TRIzol Reagent (ThermoFischer) according to the manufacturer’s 
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instruction. Samples were treated with DNase I (Promega) and cDNA generated using the high Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems). vTR and EBER expression levels in the corresponding viruses 
were normalized to the expression levels of viral ICP4 and cellular GAPDH genes. Primers and probes used for 
qRT-PCR are shown in Table 1.
Plaque size assays and growth kinetics. Virus replication and spread was determined by plaque size 
assays and multi-step growth kinetics as described previously35. For plaque size assays, at least 50 randomly 
selected plaques were captured and plaque areas were determined using Image J software (NIH). Significant dif-
ference in plaque diameters was evaluated by One-way analysis of variance (ANOVA).
Ethics statement and in vivo experiments. All animal work was conducted according to relevant 
national and international guidelines for humane use of animals. Animal experiments were approved by the 
Landesamt für Gesundheit und Soziales (LAGeSo) in Berlin (approval number G0218/12). One-day old specific 
pathogen free (SPF) chickens (ValoBioMedia) were randomly assigned into four groups. Animals were infected 
subcutaneously with 2000 PFU of either wild type vRB-1B (n = 9), v∆vTR (n = 25), vEBER-1 (n = 25), vEBER-2 
(n = 23) or the revertant virus vRev (n = 24). Peripheral blood samples were collected from the infected chickens 
at 4, 7, 10, 14, 21 and 28 dpi to determine MDV genome copy numbers in the blood, as described previously34,36. 
Chickens were monitored for clinical symptoms of MD on a daily basis throughout the 91 days of the experiment. 
To eliminate bias, the animal experiment was performed in a blinded manner until all data was collected and eval-
uated to avoid subjectivity. Animals were euthanized and examined for tumor lesions either once clinical symp-
toms were evident or after termination of the experiment. To confirm the presence of the introduced mutations 
in the virus genome, DNA was extracted from tumor tissue and the target region analyzed by Sanger sequencing.
Quantification of MDV genome copies. DNA was extracted from the blood of the infected chickens 
using the E-Z96 blood DNA kit (OMEGA biotek, USA) following the manufacturer’s instructions. MDV genome 
copies were determined by quantitative PCR (qPCR) using specific primers and a probe for the MDV ICP4 gene 
(Table 1)37,38. ICP4 copy numbers were normalized to cellular inducible nitric oxide synthase (iNOS) gene as 
described previously39.








































Table 1. Primers and probes for qRT-PCR, qPCR, DNA sequencing, and construction of the recombinant 
viruses.
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Statistical analyses. The statistical analyses were performed using Graph-Pad Prism v7 and the SPSS soft-
ware (SPSS, Inc). Plaque size assays were analyzed using one-way analysis of variance (ANOVA). MDV genome 
qPCR data were analyzed using the Kruskal-Wallis test. Data sets were first tested for normal distribution and 
results were considered significant when p < 0.05. Animal experiment data was analyzed by Fisher’s exact test, 
with a Bonferroni correction for multiple comparisons and results were considered significant when p < 0.0125.
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